|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We found that high TS expression was significantly more common in intestinal than in diffuse type of gastric cancer according to Lauren classification (P=0.0003); in type I carcinomas compared to type IV according to Goseki classification (P=0.002); and in gastric cancers in men than women (P=0.04).
|
27240805 |
2017 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Relative cDNA quantification of ribonucleotide reductase, large subunit 1, excision repair cross-complementation group 1, thymidylate synthase and topoisomerase IIa genes was tested using real-time PCR on microdissected neuroendocrine and nonneuroendocrine tumor components of 42 mixed cases (from the lung as well as the gastrointestinal and genitourinary tracts) and on 45 control cases of pure neuroendocrine and nonneuroendocrine carcinomas.
|
25633872 |
2015 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We have designed four gene molecular beacon (MB) probes for multiplex quantitative real-time polymerase chain reactions to examine RRM1, XRCC1, TUBB3 and TS mRNA expression in paraffin-embedded specimens from 50 patients with advanced or metastatic carcinomas.
|
24935362 |
2014 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A series of 69 thymic neoplasms (7 A-, 6 AB-, 6 B1-, 10 B2-, 14 B3-thymomas, 22 carcinomas and 4 combined tumors) was collected to assess gene expression of thymidylate synthase (TS), excision repair cross complementing-1 (ERCC1), ribonucleotide reductase subunit 1 (RRM1), topoisomerase 2α (TOP2A) and mTOR.
|
23276504 |
2013 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
This information may be useful in predicting the effects of TS-inhibiting agents in patients with NSCLC and HGNE carcinomas of the lung.
|
20578072 |
2010 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The carcinomas were classified into two sets of four groups each using the overall median levels of TS and DPD or TS and OPRT as cutoff values.
|
19020767 |
2008 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Thymidylate synthase expression in colon carcinomas with microsatellite instability.
|
16675565 |
2006 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Data from the current study consistently indicated higher TS expression levels in squamous cell and in high-grade carcinomas.
|
16955506 |
2006 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Thymidylate synthase (TS), a critical target in fluorouracil-based chemotherapy, is a prognostic marker in colon carcinomas and a predictor of response to treatment.
|
16609021 |
2006 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High-grade, undifferentiated tumours (WHO grade 3) had significantly higher mRNA levels of TS with respect to moderately differentiated (WHO grade 2) carcinomas (0.38+/-0.37 vs. 0.00+/-0.44, respectively; P<0.05).
|
17047489 |
2006 |